Desentum

Espoo, Finland

Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.

$12.9M raised

Feb 2024

Venture - Series Unknown

Top Investors

European Innovation CouncilSpringvestCascara VenturesVTT VenturesLuxembourgian ACME Investments

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Desentum raised?

Desentum has raised $12.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2024.

Who are Desentum's investors?

Desentum's investors include European Innovation Council, Springvest, Cascara Ventures, VTT Ventures, Luxembourgian ACME Investments.

Where is Desentum headquartered?

Desentum is headquartered in Espoo, Finland.

What does Desentum do?

Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.

What stage is Desentum at?

Desentum is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 8, 2024.

MLA

"Desentum — Funding & Investors." VCBacked, February 8, 2024, https://www.vcbacked.co/company/desentum. Accessed June 3, 2026.

APA

VCBacked. (2024). Desentum — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/desentum

Wikipedia (cite web)

{{cite web |title=Desentum — Funding & Investors |url=https://www.vcbacked.co/company/desentum |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 8, 2024.